WHA17.39 - Clinical and Pharmacological Evaluation of Drugs. WHA resolution; The Seventeenth World Health Assembly, 1964
(1964; 1 page) [French] [Russian] [Spanish]

Resumen

REQUESTS the Director-General :

  1. to continue to collect and disseminate decisions relating to adverse drug reactions as specified in resolution WHA16.36 and to report to the Executive Board if and when changes in these arrangements appear desirable;
  2. to pursue, with the assistance of the Advisory Committee on Medical Research, and with a view to eventual international co-ordination, discussion on satisfactory methods for monitoring adverse reactions, especially late toxic effects, of drugs already in use; and
  3. to undertake, with the assistance of the Advisory Committee on Medical Research, the formulation of generally acceptable principles and requirements for the evaluation of the safety and efficacy of drugs.
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019